Commentary|Videos|January 7, 2025
Advances in Managing Brain Metastases in RCC
Author(s)Manmeet Ahluwalia, MD
Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.
Manmeet Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief of medical oncology, deputy director, and Fernandez Family endowed chair in cancer research at the Baptist Health Miami Cancer Institute, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma (RCC).
According to Ahluwalia, the outcomes for patients with kidney cancer has improved over the years, yet kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma. While he notes that it can be challenging to predict the exact proportion of patients with kidney cancer who will develop brain metastases, Ahluwalia estimates it to be approximately 10% to 15% of patients with stage IV disease.
Findings
Transcription:
0:10 | As the outcomes of kidney cancer have improved, we do know that the brain is a sanctuary site, and we are seeing an increasing incidence of brain metastases in patients with kidney cancer. In fact, kidney cancer has become the fourth most common cancer that goes to the brain after lung cancer, breast cancer and melanoma.
0:30 | However, it is difficult to predict exactly what proportion of patients with kidney cancer will get brain metastases. We think it is probably in the ballpark of 10% to 15% with stage IV kidney cancer.
REFERENCE:
Podder V, Ganiyani MA, Ahmad S, et al. Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis. J Clin Oncol. 42, 2024 (suppl 16; abstr 4561). doi: 10.1200/JCO.2024.42.16_suppl.4561
Related Content
Advertisement
